Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03964168 · ClinicalTrials.gov registry record
An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers
A clinical trial, sponsored by Psoriasis Treatment Center of Central New Jersey.
- Completed
- Registry status
- 3
- Enrollment target
NCT03964168: Completed study, sponsored by Psoriasis Treatment Center of Central New Jersey.
NCT03964168 is a clinical trial that has completed, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03964168 has completed, sponsored by Psoriasis Treatment Center of Central New Jersey.
- COMPLETED
- Registry status
- 3 participants
- Enrollment target
Study Summary
Patient interviews to evaluate the reason patients discontinue biologic therapy and/or fail to follow up with provider.
Primary Outcome
Tally number of patients who discontinued due to adverse events, insurance issues or category other.
Interventions
- DRUG Biologic Agent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-07-31 |
| Est. Completion | 2020-03-03 |
What the finished NCT03964168 record still lists
NCT03964168 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Biologic Agent is the first listed.
NCT03964168 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03964168 about?
NCT03964168 is a clinical study titled "An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers". Patient interviews to evaluate the reason patients discontinue biologic therapy and/or fail to follow up with provider.
What is the current status of trial NCT03964168?
This trial is currently completed. The enrollment target is 3 participants. The study started on 2019-07-31. Estimated completion is 2020-03-03.
What interventions are being tested in trial NCT03964168?
The interventions under investigation include: Biologic Agent (DRUG).
Who is sponsoring clinical trial NCT03964168?
This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI